Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients
The second-generation hepatitis C virus (HCV) enzyme immunoassay (EIA 2), an antibody-detection test, has high sensitivity and is one of the recommended screening tests for detecting HCV infection in the United States. However, its sensitivity among oncology patients is unknown. Assess the EIA 2 sen...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical virology 2006, Vol.35 (1), p.21-25 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 25 |
|---|---|
| container_issue | 1 |
| container_start_page | 21 |
| container_title | Journal of clinical virology |
| container_volume | 35 |
| creator | Macedo de Oliveira, Alexandre White, Kathryn L. Beecham, Brady D. Leschinsky, Dennis P. Foley, Brett P. Dockter, Janel Giachetti, Cristina Safranek, Thomas J. |
| description | The second-generation hepatitis C virus (HCV) enzyme immunoassay (EIA 2), an antibody-detection test, has high sensitivity and is one of the recommended screening tests for detecting HCV infection in the United States. However, its sensitivity among oncology patients is unknown.
Assess the EIA 2 sensitivity among a group of oncology patients at a Nebraska clinic where an HCV outbreak occurred during 2000–2001 using nucleic acid testing (NAT) and recombinant immunoblot assay (RIBA) as the gold standards.
Serum specimens were collected from patients 16 months after transmission had stopped. We tested the specimens using EIA 2 (Abbott HCV EIA 2.0), a NAT assay based on transcription-mediated amplification (TMA) (Gen-Probe TMA assay) and RIBA (Chiron RIBA
® HCV 3.0 SIA). HCV infection was defined as a positive RIBA or TMA test in an oncology patient. Alanine aminotransferase (ALT) levels were determined in EIA 2-negative/TMA-positive samples.
A total of 264 samples were included in the study. We identified 92 HCV infections, 76 of which were Abbott EIA 2 positive. Abbott EIA 2 sensitivity was 83% (76/92), lower than that reported among healthy adults (90%) (
p
=
0.01) and poor sensitivity was associated with receipt of chemotherapy during the outbreak period (
p
=
0.02). Only 1 (6%) of the 16 EIA 2-negative cases had elevated ALT.
In this study, EIA 2 sensitivity among oncology patients was lower than that previously reported among immunocompetent persons. Impaired antibody production related to cancer and/or chemotherapy might explain the reduced sensitivity. These findings indicate that, when assessing HCV status in oncology patients, a NAT test should be routinely considered in addition to EIA. |
| doi_str_mv | 10.1016/j.jcv.2005.03.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67600985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1386653205001046</els_id><sourcerecordid>17082784</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-f7399f498f43bb2b11b24b304fe992266444e29fe97f436574c92ce71dad73483</originalsourceid><addsrcrecordid>eNqF0U2r1DAUBuAiivdDf4AbyUZ3rflq0uBKBr0KF1yo65CmJ2OGNhmTdrj115txCnenqyTkOYfDeavqFcENwUS8OzQHe2ooxm2DWYOxeFJdk06yulVCPi131olatIxeVTc5HzAmLePyeXVFWkWJatvr6uEbhOxnf_LziqJDGWwMQ72HAMnMPgYE4fc6AfLTtIRocjYrcjGhAWawf0Gp-gnHgmef0Q6dfFoy8sFt32aKYY9isHGM-xWdIYQ5v6ieOTNmeLmdt9WPTx-_7z7X91_vvuw-3NeWEzrXTjKlHFed46zvaU9IT3nPMHegFKVCcM6BqvKSRYhWcquoBUkGM0jGO3Zbvb30Pab4a4E868lnC-NoAsQlayEFxqpr_wuJxB2VHS-QXKBNMecETh-Tn0xaNcH6nIs-6JKLPueiMdMll1Lzemu-9BMMjxVbEAW82YDJ1owumWB9fnSSY44ZKe79xUHZ2clD0tmWfVoYfCoL10P0_xjjD3darNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17082784</pqid></control><display><type>article</type><title>Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Macedo de Oliveira, Alexandre ; White, Kathryn L. ; Beecham, Brady D. ; Leschinsky, Dennis P. ; Foley, Brett P. ; Dockter, Janel ; Giachetti, Cristina ; Safranek, Thomas J.</creator><creatorcontrib>Macedo de Oliveira, Alexandre ; White, Kathryn L. ; Beecham, Brady D. ; Leschinsky, Dennis P. ; Foley, Brett P. ; Dockter, Janel ; Giachetti, Cristina ; Safranek, Thomas J.</creatorcontrib><description>The second-generation hepatitis C virus (HCV) enzyme immunoassay (EIA 2), an antibody-detection test, has high sensitivity and is one of the recommended screening tests for detecting HCV infection in the United States. However, its sensitivity among oncology patients is unknown.
Assess the EIA 2 sensitivity among a group of oncology patients at a Nebraska clinic where an HCV outbreak occurred during 2000–2001 using nucleic acid testing (NAT) and recombinant immunoblot assay (RIBA) as the gold standards.
Serum specimens were collected from patients 16 months after transmission had stopped. We tested the specimens using EIA 2 (Abbott HCV EIA 2.0), a NAT assay based on transcription-mediated amplification (TMA) (Gen-Probe TMA assay) and RIBA (Chiron RIBA
® HCV 3.0 SIA). HCV infection was defined as a positive RIBA or TMA test in an oncology patient. Alanine aminotransferase (ALT) levels were determined in EIA 2-negative/TMA-positive samples.
A total of 264 samples were included in the study. We identified 92 HCV infections, 76 of which were Abbott EIA 2 positive. Abbott EIA 2 sensitivity was 83% (76/92), lower than that reported among healthy adults (90%) (
p
=
0.01) and poor sensitivity was associated with receipt of chemotherapy during the outbreak period (
p
=
0.02). Only 1 (6%) of the 16 EIA 2-negative cases had elevated ALT.
In this study, EIA 2 sensitivity among oncology patients was lower than that previously reported among immunocompetent persons. Impaired antibody production related to cancer and/or chemotherapy might explain the reduced sensitivity. These findings indicate that, when assessing HCV status in oncology patients, a NAT test should be routinely considered in addition to EIA.</description><identifier>ISSN: 1386-6532</identifier><identifier>EISSN: 1873-5967</identifier><identifier>DOI: 10.1016/j.jcv.2005.03.006</identifier><identifier>PMID: 15921955</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Action of physical and chemical agents ; Aged ; Biological and medical sciences ; Chemotherapy ; Disease Outbreaks ; Female ; Fundamental and applied biological sciences. Psychology ; Hepacivirus - immunology ; Hepatitis C - diagnosis ; Hepatitis C - epidemiology ; Hepatitis C - virology ; Hepatitis C Antibodies - blood ; Hepatitis C virus ; Human viral diseases ; Humans ; Immunoenzyme Techniques ; Immunosuppression ; Infectious diseases ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Miscellaneous ; Neoplasms - complications ; Oncology ; Sensitivity ; Sensitivity and Specificity ; Viral diseases ; Viral hepatitis ; Virology</subject><ispartof>Journal of clinical virology, 2006, Vol.35 (1), p.21-25</ispartof><rights>2005 Elsevier B.V.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-f7399f498f43bb2b11b24b304fe992266444e29fe97f436574c92ce71dad73483</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcv.2005.03.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17404031$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15921955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Macedo de Oliveira, Alexandre</creatorcontrib><creatorcontrib>White, Kathryn L.</creatorcontrib><creatorcontrib>Beecham, Brady D.</creatorcontrib><creatorcontrib>Leschinsky, Dennis P.</creatorcontrib><creatorcontrib>Foley, Brett P.</creatorcontrib><creatorcontrib>Dockter, Janel</creatorcontrib><creatorcontrib>Giachetti, Cristina</creatorcontrib><creatorcontrib>Safranek, Thomas J.</creatorcontrib><title>Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients</title><title>Journal of clinical virology</title><addtitle>J Clin Virol</addtitle><description>The second-generation hepatitis C virus (HCV) enzyme immunoassay (EIA 2), an antibody-detection test, has high sensitivity and is one of the recommended screening tests for detecting HCV infection in the United States. However, its sensitivity among oncology patients is unknown.
Assess the EIA 2 sensitivity among a group of oncology patients at a Nebraska clinic where an HCV outbreak occurred during 2000–2001 using nucleic acid testing (NAT) and recombinant immunoblot assay (RIBA) as the gold standards.
Serum specimens were collected from patients 16 months after transmission had stopped. We tested the specimens using EIA 2 (Abbott HCV EIA 2.0), a NAT assay based on transcription-mediated amplification (TMA) (Gen-Probe TMA assay) and RIBA (Chiron RIBA
® HCV 3.0 SIA). HCV infection was defined as a positive RIBA or TMA test in an oncology patient. Alanine aminotransferase (ALT) levels were determined in EIA 2-negative/TMA-positive samples.
A total of 264 samples were included in the study. We identified 92 HCV infections, 76 of which were Abbott EIA 2 positive. Abbott EIA 2 sensitivity was 83% (76/92), lower than that reported among healthy adults (90%) (
p
=
0.01) and poor sensitivity was associated with receipt of chemotherapy during the outbreak period (
p
=
0.02). Only 1 (6%) of the 16 EIA 2-negative cases had elevated ALT.
In this study, EIA 2 sensitivity among oncology patients was lower than that previously reported among immunocompetent persons. Impaired antibody production related to cancer and/or chemotherapy might explain the reduced sensitivity. These findings indicate that, when assessing HCV status in oncology patients, a NAT test should be routinely considered in addition to EIA.</description><subject>Action of physical and chemical agents</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Disease Outbreaks</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hepacivirus - immunology</subject><subject>Hepatitis C - diagnosis</subject><subject>Hepatitis C - epidemiology</subject><subject>Hepatitis C - virology</subject><subject>Hepatitis C Antibodies - blood</subject><subject>Hepatitis C virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Immunosuppression</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Neoplasms - complications</subject><subject>Oncology</subject><subject>Sensitivity</subject><subject>Sensitivity and Specificity</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Virology</subject><issn>1386-6532</issn><issn>1873-5967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U2r1DAUBuAiivdDf4AbyUZ3rflq0uBKBr0KF1yo65CmJ2OGNhmTdrj115txCnenqyTkOYfDeavqFcENwUS8OzQHe2ooxm2DWYOxeFJdk06yulVCPi131olatIxeVTc5HzAmLePyeXVFWkWJatvr6uEbhOxnf_LziqJDGWwMQ72HAMnMPgYE4fc6AfLTtIRocjYrcjGhAWawf0Gp-gnHgmef0Q6dfFoy8sFt32aKYY9isHGM-xWdIYQ5v6ieOTNmeLmdt9WPTx-_7z7X91_vvuw-3NeWEzrXTjKlHFed46zvaU9IT3nPMHegFKVCcM6BqvKSRYhWcquoBUkGM0jGO3Zbvb30Pab4a4E868lnC-NoAsQlayEFxqpr_wuJxB2VHS-QXKBNMecETh-Tn0xaNcH6nIs-6JKLPueiMdMll1Lzemu-9BMMjxVbEAW82YDJ1owumWB9fnSSY44ZKe79xUHZ2clD0tmWfVoYfCoL10P0_xjjD3darNQ</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Macedo de Oliveira, Alexandre</creator><creator>White, Kathryn L.</creator><creator>Beecham, Brady D.</creator><creator>Leschinsky, Dennis P.</creator><creator>Foley, Brett P.</creator><creator>Dockter, Janel</creator><creator>Giachetti, Cristina</creator><creator>Safranek, Thomas J.</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>2006</creationdate><title>Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients</title><author>Macedo de Oliveira, Alexandre ; White, Kathryn L. ; Beecham, Brady D. ; Leschinsky, Dennis P. ; Foley, Brett P. ; Dockter, Janel ; Giachetti, Cristina ; Safranek, Thomas J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-f7399f498f43bb2b11b24b304fe992266444e29fe97f436574c92ce71dad73483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Action of physical and chemical agents</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Disease Outbreaks</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hepacivirus - immunology</topic><topic>Hepatitis C - diagnosis</topic><topic>Hepatitis C - epidemiology</topic><topic>Hepatitis C - virology</topic><topic>Hepatitis C Antibodies - blood</topic><topic>Hepatitis C virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Immunosuppression</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Neoplasms - complications</topic><topic>Oncology</topic><topic>Sensitivity</topic><topic>Sensitivity and Specificity</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Macedo de Oliveira, Alexandre</creatorcontrib><creatorcontrib>White, Kathryn L.</creatorcontrib><creatorcontrib>Beecham, Brady D.</creatorcontrib><creatorcontrib>Leschinsky, Dennis P.</creatorcontrib><creatorcontrib>Foley, Brett P.</creatorcontrib><creatorcontrib>Dockter, Janel</creatorcontrib><creatorcontrib>Giachetti, Cristina</creatorcontrib><creatorcontrib>Safranek, Thomas J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Macedo de Oliveira, Alexandre</au><au>White, Kathryn L.</au><au>Beecham, Brady D.</au><au>Leschinsky, Dennis P.</au><au>Foley, Brett P.</au><au>Dockter, Janel</au><au>Giachetti, Cristina</au><au>Safranek, Thomas J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients</atitle><jtitle>Journal of clinical virology</jtitle><addtitle>J Clin Virol</addtitle><date>2006</date><risdate>2006</risdate><volume>35</volume><issue>1</issue><spage>21</spage><epage>25</epage><pages>21-25</pages><issn>1386-6532</issn><eissn>1873-5967</eissn><abstract>The second-generation hepatitis C virus (HCV) enzyme immunoassay (EIA 2), an antibody-detection test, has high sensitivity and is one of the recommended screening tests for detecting HCV infection in the United States. However, its sensitivity among oncology patients is unknown.
Assess the EIA 2 sensitivity among a group of oncology patients at a Nebraska clinic where an HCV outbreak occurred during 2000–2001 using nucleic acid testing (NAT) and recombinant immunoblot assay (RIBA) as the gold standards.
Serum specimens were collected from patients 16 months after transmission had stopped. We tested the specimens using EIA 2 (Abbott HCV EIA 2.0), a NAT assay based on transcription-mediated amplification (TMA) (Gen-Probe TMA assay) and RIBA (Chiron RIBA
® HCV 3.0 SIA). HCV infection was defined as a positive RIBA or TMA test in an oncology patient. Alanine aminotransferase (ALT) levels were determined in EIA 2-negative/TMA-positive samples.
A total of 264 samples were included in the study. We identified 92 HCV infections, 76 of which were Abbott EIA 2 positive. Abbott EIA 2 sensitivity was 83% (76/92), lower than that reported among healthy adults (90%) (
p
=
0.01) and poor sensitivity was associated with receipt of chemotherapy during the outbreak period (
p
=
0.02). Only 1 (6%) of the 16 EIA 2-negative cases had elevated ALT.
In this study, EIA 2 sensitivity among oncology patients was lower than that previously reported among immunocompetent persons. Impaired antibody production related to cancer and/or chemotherapy might explain the reduced sensitivity. These findings indicate that, when assessing HCV status in oncology patients, a NAT test should be routinely considered in addition to EIA.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>15921955</pmid><doi>10.1016/j.jcv.2005.03.006</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6532 |
| ispartof | Journal of clinical virology, 2006, Vol.35 (1), p.21-25 |
| issn | 1386-6532 1873-5967 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67600985 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Action of physical and chemical agents Aged Biological and medical sciences Chemotherapy Disease Outbreaks Female Fundamental and applied biological sciences. Psychology Hepacivirus - immunology Hepatitis C - diagnosis Hepatitis C - epidemiology Hepatitis C - virology Hepatitis C Antibodies - blood Hepatitis C virus Human viral diseases Humans Immunoenzyme Techniques Immunosuppression Infectious diseases Male Medical sciences Microbiology Middle Aged Miscellaneous Neoplasms - complications Oncology Sensitivity Sensitivity and Specificity Viral diseases Viral hepatitis Virology |
| title | Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A20%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sensitivity%20of%20second-generation%20enzyme%20immunoassay%20for%20detection%20of%20hepatitis%20C%20virus%20infection%20among%20oncology%20patients&rft.jtitle=Journal%20of%20clinical%20virology&rft.au=Macedo%20de%20Oliveira,%20Alexandre&rft.date=2006&rft.volume=35&rft.issue=1&rft.spage=21&rft.epage=25&rft.pages=21-25&rft.issn=1386-6532&rft.eissn=1873-5967&rft_id=info:doi/10.1016/j.jcv.2005.03.006&rft_dat=%3Cproquest_cross%3E17082784%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17082784&rft_id=info:pmid/15921955&rft_els_id=S1386653205001046&rfr_iscdi=true |